Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Clara Domke"'
Autor:
Pamela A. Trail, Victor Levitsky, Martin Behe, Mariam Gachechiladze, Francesca Malvezzi, Tamara Lekishvili, Ralph Bessey, Omar Abdelmotaleb, Sarah Jetzer, Sophie Barsin, Clara Domke, Niina Veitonmäki, Nicolò Rigamonti
The CD40 receptor is an attractive target for cancer immunotherapy. Although a modest pharmacodynamic effect is seen in patients following administration of CD40-targeting monoclonal antibodies (mAb), the doses that could be safely administered do no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f758c44c68938d1700ee6ca92c51e93
https://doi.org/10.1158/2326-6066.c.6550722
https://doi.org/10.1158/2326-6066.c.6550722
Autor:
Pamela A. Trail, Victor Levitsky, Martin Behe, Mariam Gachechiladze, Francesca Malvezzi, Tamara Lekishvili, Ralph Bessey, Omar Abdelmotaleb, Sarah Jetzer, Sophie Barsin, Clara Domke, Niina Veitonmäki, Nicolò Rigamonti
Supplementary Figure from A Multispecific Anti-CD40 DARPin Construct Induces Tumor-Selective CD40 Activation and Tumor Regression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15235671a7926d2505aafe6d58da6409
https://doi.org/10.1158/2326-6066.22544685.v1
https://doi.org/10.1158/2326-6066.22544685.v1
Autor:
Nicolò Rigamonti, Niina Veitonmäki, Clara Domke, Sophie Barsin, Sarah Jetzer, Omar Abdelmotaleb, Ralph Bessey, Tamara Lekishvili, Francesca Malvezzi, Mariam Gachechiladze, Martin Behe, Victor Levitsky, Pamela A. Trail
Publikováno v:
Cancer Immunology Research. 10:626-640
The CD40 receptor is an attractive target for cancer immunotherapy. Although a modest pharmacodynamic effect is seen in patients following administration of CD40-targeting monoclonal antibodies (mAb), the doses that could be safely administered do no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::252f0d164ff05d5739f16ab5208d8169
https://doi.org/10.1158/2326-6066.cir-21-0553
https://doi.org/10.1158/2326-6066.cir-21-0553
Autor:
Hong Ji, Clara Domke, Julia M. Martinez-Gomez, Sarah Jetzer, Kyriaki Ioannou, Philippe Legenne, Ivana Tosevski, Sophie Barsin, Mariam Gachechiladze, Nicolo Rigamonti, Simone Ragusa, Tamara Lekishvili, Rupert Kenefeck, Vladimir Kirkin, Joanna Roquette, Mitch Levesque, Karolin Rommel, Ana Florescu, Eliane Müller, Anne Goubier
Publikováno v:
Cancer Research. 81:1733-1733
Therapeutic agonists targeting CD40 have shown encouraging signs of anti-tumor efficacy in patients. Despite their initial promise however, optimal dosing of systemically active agents has been limited by toxicity and their full therapeutic potential
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::66f1f710b47511b8fc99987423ea61cd
https://doi.org/10.1158/1538-7445.am2021-1733
https://doi.org/10.1158/1538-7445.am2021-1733